Welcome to our dedicated page for Perspective Therapeutics news (Ticker: CATX), a resource for investors and traders seeking the latest updates and insights on Perspective Therapeutics stock.
Perspective Therapeutics, Inc. (NYSE American: CATX) is a radiopharmaceutical development company focused on 212Pb-based theranostic treatments and imaging for cancer. The CATX news page on Stock Titan aggregates company announcements, clinical data updates, conference presentations, financial disclosures, and other material events drawn from press releases and SEC filings.
According to recent communications, Perspective regularly reports interim results from its Phase 1/2a trials of [212Pb]VMT-α-NET in SSTR2-positive neuroendocrine tumors, VMT01 in melanoma patients with MC1R-positive imaging scans, and PSV359 in FAP-α-positive solid tumors. News items often summarize safety findings, investigator-assessed anti-tumor activity, and progress across dose cohorts, along with plans for data presentations at major meetings such as ASCO, ASCO-GI, ESMO, NANETS, and AACR-NCI-EORTC conferences.
Investors and observers can also find updates on corporate presentations, participation in healthcare and biopharma conferences, and periodic business highlights tied to quarterly financial results. Form 8-K filings referenced in the news flow include earnings releases, updated corporate slide decks, and information about executive appointments and employment agreements.
For anyone tracking CATX, this news feed provides a centralized view of Perspective’s clinical development trajectory, manufacturing expansion efforts around its proprietary 212Pb generator, and key corporate developments. Users interested in radiopharmaceutical and oncology catalysts may wish to revisit this page around major medical congresses, scheduled earnings dates, and company-announced business updates.
Perspective Therapeutics (NYSE AMERICAN: CATX) has provided strategic updates and priorities for the next 12-18 months. The company reported preliminary unaudited cash and equivalents of $227.8M as of December 31, 2024, expected to fund operations into late 2026.
The company is advancing three clinical programs: VMT-α-NET for neuroendocrine tumors, which has shown promising safety data and clinical activity in 18 patients; VMT01 for melanoma treatment, demonstrating favorable safety profile and some clinical responses; and PSV359, a new asset targeting FAP-α in solid tumors, with potential enrollment starting mid-2025.
Additionally, four new assets are being evaluated for IND development. The company is expanding its manufacturing capabilities through improving existing facilities and developing recently acquired sites.
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focusing on advanced cancer treatments, has announced its participation in two major healthcare conferences in San Francisco.
CEO Thijs Spoor will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, from 3:45 p.m. to 4:25 p.m. PT at The Westin St. Francis Hotel's Elizabethan B room. Additionally, the company will present at the Biotech Showcase conference on Tuesday, January 14, 2025, at 1:30 p.m. PT, taking place at the Hilton San Francisco - Union Square's Yosemite A Ballroom.
The management team will be available for one-on-one meetings with investors and strategic partners at both conferences, with interested parties directed to contact events@perspectivetherapeutics.com for scheduling.
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, has appointed Juan Graham as its new Chief Financial Officer (CFO) effective January 6, 2025. Jonathan Hunt, the former CFO, will transition to the role of Chief Accounting Officer (CAO). The company's CEO, Thijs Spoor, emphasized the strategic importance of this change as Perspective advances its radiopharmaceutical technology platform and builds manufacturing infrastructure.
Mr. Graham brings nearly 25 years of global experience in life sciences, having previously served as CFO at FibroGen, where he led global finance, capital formation, and strategic initiatives. Before that, he held various finance and business development roles at Johnson & Johnson. Mr. Graham holds an MBA from McGill University and a bachelor's degree from Tec de Monterrey.
Perspective Therapeutics has delivered initial clinical data for two new potential medicines and plans to advance further clinical programs and new initiatives under Mr. Graham's financial leadership.
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focused on cancer treatments, has announced its participation in two major investor conferences in December 2024. The company's senior leadership will be available for one-on-one meetings with investors at both events.
The first appearance will be at the 36th Annual Piper Healthcare Conference in New York on December 3, featuring a fireside chat from 10:00-10:25 AM ET. The second event is the 7th Annual Evercore HealthCONx in Coral Gables, FL on December 5, with a fireside chat scheduled for 10:50-11:10 AM ET. Both events will be webcasted and available for replay for 90 days through the company's investor website.
Perspective Therapeutics announced initial results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for neuroendocrine tumors at the 2024 NANETS Symposium. The trial showed favorable safety profile with no dose-limiting toxicities at tested doses (2.5 and 5.0 mCi). Eight of nine patients achieved durable disease control, with six showing measurable tumor volume reduction. One patient achieved confirmed response per RECIST v1.1. The Safety Monitoring Committee recommended proceeding with dose escalation and expanding patient enrollment at 5.0 mCi. The company plans to consult with FDA for Cohort 3 initiation.
Perspective Therapeutics (NYSE AMERICAN: CATX) announced the upcoming presentation of initial results from their Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 NANETS Multidisciplinary NET Medical Symposium. The presentation, titled 'Preliminary safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 expressing neuroendocrine tumors,' will be delivered by Dr. Richard L. Wahl on November 22, 2024. The company will host a conference call on November 21 to discuss the data, featuring Dr. Wahl and including a Q&A session.
Perspective Therapeutics (NYSE AMERICAN: CATX) reported Q3 2024 financial results and business updates. The company has $267.8 million in cash and investments, expected to fund operations into mid-2026. Key developments include advancing [212Pb]VMT01 trials in melanoma patients and [212Pb]VMT-α-NET in neuroendocrine tumors. The company started shipping from a second manufacturing facility in Somerset, New Jersey, and purchased additional facilities in Houston, Chicago, and Los Angeles. Q3 2024 showed a net loss of $15.1 million ($0.21 per share), with research and development expenses at $12.0 million and general administrative expenses at $7.0 million.
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, will report its third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024 after the market closes. The press release will be available in the newsroom section of the Company's website.
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focusing on cancer treatments, has announced its participation in four major investor conferences this November. The company will attend the Truist Securities BioPharma Symposium (Nov 7) in New York for one-on-one meetings, the UBS Global Healthcare Conference (Nov 13) in California featuring a fireside chat, the Stifel Healthcare Conference (Nov 18) in New York with a fireside chat, and the Jefferies London Healthcare Conference (Nov 19-21) for one-on-one meetings. Webcasts of applicable events will be available live and archived for 90 days on the company's investor website.
Perspective Therapeutics (NYSE AMERICAN: CATX) presented six updates on its radiopharmaceutical programs at the 37th Annual EANM Congress in Hamburg. The presentations included preclinical studies and first-in-human imaging data for [212Pb]Pb-PSV359, showing strong tumor uptake and anti-tumor efficacy. Updates on [212Pb]Pb-VMT-α-NET revealed promising interim clinical results in NET patients, with confirmed tumor responses in six of ten GEP-NETs patients. The presentations also covered biodistribution studies, chelator evaluations, and development of imaging surrogates for therapeutic radiopharmaceuticals.